Processa Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PCSA)
CUSIP: 74275C403
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 2,351,108
- Total 13F shares
- 115,174
- Share change
- +115,174
- Total reported value
- $330,990
- Price per share
- $2.88
- Number of holders
- 10
- Value change
- +$330,990
- Number of buys
- 10
Quarterly Holders Quick Answers
What is CUSIP 74275C403?
CUSIP 74275C403 identifies PCSA - Processa Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q1 2026
Recent filing periods for CUSIP 74275C403:
Top shareholders of PCSA - Processa Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Chiliz Group Ltd. |
13D/G
|
— |
11%
|
5,467,181
|
$984,093 | $0 | 05 Aug 2025 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
8.1%
|
200,000
|
$644,000 | $0 | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
2,644,376
|
$608,206 | +$475,127 | 30 Jun 2025 | |
| 3i, LP |
13D/G
|
— |
4.9%
|
1,681,944
|
$504,583 | $0 | 17 Jun 2025 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
36%
|
1,030,200
|
$197,695 | — | 30 Sep 2025 | |
| James H. Stanker |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
36,029
mixed-class rows
|
$61,609 | — | 05 Apr 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
11%
|
303,304
|
$58,204 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
10%
|
288,212
|
$55,337 | — | 30 Sep 2025 | |
| Robert Michael Floyd |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
172,061
|
$51,618 | — | 09 Feb 2023 | |
| Virgil Thompson |
3/4/5
|
Director |
—
mixed-class rows
|
241,907
mixed-class rows
|
$42,163 | — | 27 Jun 2023 | |
| Yorke Justin W. |
3/4/5
|
Director |
—
mixed-class rows
|
660,074
mixed-class rows
|
$11,248 | — | 01 Oct 2025 | |
| Virtu Financial LLC |
13F
|
Company |
1.4%
|
40,843
|
$8,000 | — | 30 Sep 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
1.3%
|
36,248
|
$6,956 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
1.2%
|
34,051
|
$6,534 | — | 30 Sep 2025 | |
| StoneX Group Inc. |
13F
|
Company |
0.66%
|
18,951
|
$3,637 | — | 30 Sep 2025 | |
| Sassicaia Capital Advisers LLC |
13F
|
Company |
0.56%
|
15,977
|
$3,066 | — | 30 Sep 2025 | |
| Composition Wealth, LLC |
13F
|
Company |
0.35%
|
10,000
|
$1,919 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.08%
|
2,393
|
$459 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
376
|
$72 | — | 30 Sep 2025 | |
| JONES FINANCIAL COMPANIES LLLP |
13F
|
Company |
0.01%
|
188
|
$40 | — | 30 Sep 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.01%
|
154
|
$30 | — | 30 Sep 2025 | |
| Khalid Islam |
3/4/5
|
Director |
—
class O/S missing
|
18,208
|
— | — | 31 Mar 2022 |
Institutional Holders of Processa Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PCSA) as of Q4 2025
As of 31 Dec 2025,
Processa Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PCSA) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
115,174 shares.
The largest 10 holders included
JANE STREET GROUP, LLC, VANGUARD GROUP INC, HRT FINANCIAL LP, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, Stonepine Capital Management, LLC, Tower Research Capital LLC (TRC), BANK OF AMERICA CORP /DE/, JONES FINANCIAL COMPANIES LLLP, and WELLS FARGO & COMPANY/MN.
This page lists
10
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q4 2025 Across Filers
Q4 2025 holders
10
Q4 2025 holders
10
Holder diff
0
| Investor | Q4 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.